Reaction
Retinal Occlusive Vasculitis reporting signals
As of the last recalculation, Retinal Occlusive Vasculitis appears in 211 FAERS reports alongside 6 co-occurring drug terms. The strongest observed disproportionality signal is FARICIMAB (PRR 1,068.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Faricimab | 62 | 1,068.3 | 1,076.5 |
| Aflibercept | 48 | 196.2 | 196.5 |
| Atropine | 10 | 124.9 | 125.1 |
| Atropine Sulfate | 12 | 116.1 | 116.3 |
| Dorzolamide Hydrochloride And Timolol Maleate | 8 | 103.7 | 103.8 |
| Ranibizumab | 9 | 34.9 | 34.9 |